Acute promyelocytic leukemia: Clinical and morphologic features and prognostic factors

Seminars in Hematology

Volumn 38, Issue 1, 2001, Pages 4-12

  Awisati, Giuseppe ^a   Lo Coco, Francesco ^a,b   Mandelli, Franco ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLEEDING TENDENCY; CLINICAL FEATURE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; IMMUNOPHENOTYPING; LEUKOCYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTE; PROTEIN DEGRADATION; THROMBOCYTOPENIA;

EID: 0035145671     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90001-0     Document Type: Article

References (82)

1. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
2. Epidemiology of acute promyelocytic leukemia in Italy
3. The coagulopathy in acute promyelocytic leukemia: DIC?
4. Acquired alpha 2-antiplasmin deficiency in acute promyelocytic leukemia
5. Event-free survival (EFS) duration in newly diagnosed acute promyelocytic leukemia (APL) is favorably influenced by induction treatment with idarubicin alone: Final results of the GIMEMA randomised study LAP0389 comparing IDA vs IDA + ARA-C in newly diagnosed APL
6. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukemia
7. Proposal for the classification of the acute leukemias
8. A variant form of hypergranular promyelocytic leukemia
9. Platelet and fibrinogen survival in acute promyelocytic leukemia
10. The very acute leukemias
11. La leucose aiguë à promyélocytes. Etude portant sur 20 observations
12. Acute promyelocytic leukemia. Results of treatment with daunorubicin
13. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint
14. Acute promyelocytic leukemia in children: Experience of the Italian Pediatric Hematology Oncology Group (AIEOP)
15. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
16. Correlation of CD2 expression with PML gene breakpoints, in patients with acute promyelocytic leukemia
17. Acute promyelocytic leukemia in 57 previously untreated patients
18. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital
19. Additional chromosomal abnormalities have no effect on the clinical outcome of patients with acute promyelocytic leukemia (APL)
20. Immunological definition of acute promyelocytic leukemia (FAB M3): A study of 39 cases
21. Is acute promyelocytic leukemia a curable disease? Treatment strategy for a long term survival
22. All-transretinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
23. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia
24. Absence of RT-PCR detectable residual disease in acute promyelocytic leukemia in long term remission
25. Early detection of relapse by prospective RT-PCR analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMAAIEOP multicenter "AIDA" trial
26. High frequency of acute promyelocytic leukemia among latinos with acute myeloid leukemia
27. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the anti-PML monoclonal antibody PG-M3
28. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
29. Acute promyelocytic leukemia: Biology and treatment
30. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Long-term follow-up confirms the superiority of ATRA combined to chemotherapy over CT alone in newly diagnosed acute promyelocytic leukemia (APL)
31. Treatment of acute promyelocytic leukemia: A report of 70 cases
32. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous ATRA and chemotherapy
33. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid
34. Prognostic significance of the RT-PCR assay of PML/RARα transcripts in acute promyelocytic leukemia
35. Characterization of acute promyelocytic leukemia cases with PML/RARα break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid
36. Association of PML/RARα fusion mRNA type with pretreatment characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study
37. Acute promyelocytic leukemia: A childhood cluster
38. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?
39. Acute promyelocytic leukemia: From genetics to treatment
40. The pathogenesis of acute promyelocytic leukemia: Evaluation of the role of molecular diagnosis and monitoring in the management of the disease
41. Clinical and biological relevance of immunophenotype in acute promyelocytic leukemia
42. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
43. Acute promyelocytic leukemia
44. Additional chromosome abnormalities confer poor prognosis in acute promyelocytic leukemia
45. Acute promyelocytic leukemia: Clinical relevance of two major PML/RARα isoforms and detection of minimal residual disease by retrotranscriptase-polymerase chain reaction
46. Acute promyelocytic leukemia: MD Anderson Hospital experience
47. Role of maintenance chemotherapy in acute promyelocytic leukemia
48. Severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid)
49. PML/RARα PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months
50. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years
51. Rearrangements of the RAR-α gene in acute promyelocytic leukemia: Correlations with morphology and immunophenotype
52. Therapy of molecular relapse in acute promyelocytic leukemia
53. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
54. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
55. Acute promyelocytic leukemia: A curable disease
56. Childhood acute promyelocytic leukemia in Nicaragua
57. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
58. Leucémie aigüe promyélocytaire: Étude retrospective de 119 malades traités par daunorubicine
59. Acute promyelocytic leukemia: A study of 39 cases with identification of a hyperbasophilic microgranular variant
60. Epidemiology of acute promyelocytic leukemia
61. Annexin II and bleeding in acute promyelocytic leukemia
62. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia
63. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction
64. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
65. The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study
66. PML/RARα transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, telapse and after bone marrow transplantation
67. Acute promyelocytic leukemia: Clinical aspects and results of treatment in 62 patients
68. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients
69. Absence of detectable PML/RARα fusion transcripts in longterm remission patients after bone marrow transplantation for acute promyelocytic leukemia
70. Acute promyelocytic leukemia. Therapy results and prognostic factors
71. Definition of relapse risk and tole of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
72. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia
73. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17) (q22;q21): A report on 50 patients
74. HLA-DR-,CD33+, CD56+, CD16-myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3
75. Secondary cytogenetic changes in acute promyelocytic leukemia: Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene. A Cancer and Leukemia Group B study
76. Molecular analysis and clinical outcome of adult APL patients with the V PML/RARα isoform: Results from Intergroup protocol 0129
77. The unique aspects of acute promyelocytic leukemia
78. Basophilic differentiation in acute promyelocytic leukemia
79. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia
80. All-trans-retinoic acid in acute promyelocytic leukemia
81. Persistence of RARα-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukemia
82. Early mortality and retinoic acid syndrome in acute promyelocytic leukemia: Impact of leucocytosis, lowdose chemotherapy, PML/RARα isoform, and CD13 expression in patients treated with all-trans retinoic acid